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ABSTRACT
Our experiments assessed the modulation of striatal acetylcho-
line (ACh) output by dopamine (DA) receptor subtypes under
physiological conditions using in vivo microdialysis in awake
rats. The degree to which the dopaminergic modulation of
stnatal cholinergic neurons might vary as a function of local
extracellular ACh level also was examined by application of
varying concentrations of the acetylcholinesterase (AChE), in-
hibitor neostigmine (NEO) in the microdialysis perfusate. Under
physiological conditions (0 NEO), the amount of ACt, in the
dialysates was 25.1 ± 2.2 fmol/20-p.l sample (n = 20) whereas
values of 67.9 ± 3.5 (n = 35) and 527.7 ± 56.1 (n = 13)
fmoV20-tl sample were obtained when the applied NEO con-
centration was 1 0 and 1 00 nM, respectively. In the absence of
NEO, a low dose of the indirect DA agonist amphetamine
(AMPH; 2 mg/kg i.p.) failed to affect striatal ACh output; a
higher AMPH dose (1 0 mg/kg i.p.) significantly decreased the
amount of ACh in dialysates. Under physiological conditions,
the direct D2-selective agonist quinpirole (3 mg/kg i.p.) de-
creased extracellular ACh in striatum to nondetectable levels
and the direct Dl -selective agonist SKF-38393 (1 0 mg/kg i.p.)
produced a significant increase in this measure. Analysis of the
changes in striatal ACh output produced by administration of
these DA compounds in the absence vs. presence of local NEO
revealed that 1 0 nM NEO did not qualitatively alter the phar-
macological responsivity of this system as compared to the
physiological condition. However, in the presence of 1 00 nM
NEO, 2 mg/kg AMPH elicited a significant increase in striatal
ACh output. At the 1 00 nM NEO concentration it also was
observed that the amplitude of the quinpirole-induced inhibition
of ACt, efflux did not increase further in proportion to basal ACh
levels whereas the amplitude of the increase in ACh output
produced by SKF-38393 was linearly related to basal ACh
levels across all NEO concentrations. Under conditions where
cholinergic pharmacological responsivity was minimally af-
fected (1 0 nM NEO), the 02 receptor antagonist haloperidol (1
mg/kg i.p.) increased stnatal ACh output by 50% and the Dl
receptor antagonist SCH-23390 (0.5 mg/kg i.p.) decreased this
variable by 41 %. Under these conditions, the inhibitory action
of quinpirole on ACh output could be reversed by subsequent
administration of AMPH (5 mg/kg i.p.) and this effect of AMPH
could then be blocked by administration of SCH-23390. Thus,
under physiological or low NEO (1 0 nM) conditions a prevalent
D2-mediated inhibition as well as an opposing Dl -mediated
excitation of striatal ACh output can be demonstrated. At a
higher NEO concentration (1 00 nM), regulation of the striatal
ACh system by DA receptor subtypes is differentially affected
such that the D2-mediated inhibitory influence no longer pre-
dominates over the Dl -mediated excitatory drive. Caution
should be exercised when interpreting ACh efflux data obtained
using microdialysis under conditions of AChE inhibition.
The demonstration of very high DA and ACh concentra-
tions in striatum, together with the numerous behavioral
and clinical observations of a reciprocal relation between the
actions of dopaminergic and cholinergic drugs, has led to the
generally accepted concept that a balance between striatal
DA and ACh activity is important for the normal function of
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that structure (Tarsy, 1977). A model in which this DA-ACh
balance is the result of an inhibitory action of DA on striatal
ACh output has received much experimental support. Early
investigations demonstrated that stimulation of DA recep-
tors by systemic administration of direct or indirect agonists
produced apparent decreases in striatal ACh function (Sethy
and Van Woert, 1974; Guyenet et at. , 1975; Ladinsky et at.,
1975; McGeer et at. , 1975). In contrast, direct or indirect
antagonism of DA receptor function by systemically admin-
istered compounds produced increases in indices of striatal
ACh utilization (Beam et at. , 1966; Stadler et at. , 1973; Tra-
bucchi et at. , 1974; Consolo et at. , 1975). Because it became
evident that DA receptors can be divided into two pharma-
cologically defined categories, the Di-like (Dl) and D2-like
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(D2) subtypes (Kebabian and Caine, 1979; Civelli et at.,
1993), the regulation of striatal ACh activity by DA has been
studied accordingly.
Extensive evidence indicates that the inhibitory effect of
DA on striatal ACh utilization, as revealed by systemic ad-
ministration of nonselective DA agonist and antagonist
drugs, is mediated by D2-like DA receptors (Lehmann and
Langer, 1983; Stoof et at. , 1992). D2-selective agonists dose-
dependently increase the ACh content ofstriatal tissue (Scat-
ton, 1982b; Wong et at. , 1983; Consolo et at. , 1987) and
decrease striatal ACh output measured with in vivo mmcro-
dialysis (Bertorelli and Consolo, 1990; Damsma et at. , 1990a;
Robertson et at. , 1993). Similarly, D2-selective antagonists
consistently elicit dose-dependent decreases in the tissue
ACh content ofstriatum (Consolo et at. , 1981; Scatton, 1982a)
and produce corresponding increases in the output of striatal
ACh in vivo (Damsma et at. , 1990a; Imperato et at. , 1993).
Finally, increases and decreases in tissue ACh levels in stri-
atum are linearly correlated with the stimulation and block-
ade of D2 receptors by selective D2 agonist and antagonist
drugs, respectively (Korf et at. , 1985; Enz et at. , 1990).
A facilitatory role ofDl-like DA receptors in the regulation
of striatal ACh activity is suggested from analyses conducted
with the more recently available D1-selective pharmacologi-
cal compounds, although the results with antagonists gener-
ally are most congruous in this regard (DiChiara and Morelli,
1993). Systemic administration of various Di-selective ago-
nists does not affect measures of ACh content in striatal
tissue (Scatton, 1982b; Consolo et at. , 1987) and either in-
creases the output of striatal ACh in vivo (Damsma et at.,
1990b, 1991; Imperato et at. , 1994) or has no effect on this
parameter (Bertorelli and Consolo, 1990). Systemic adminis-
tration of the D1-selective antagonist SCH-23390 consis-
tently increases the tissue content of ACh in striatum (Fage
and Scatton, 1986; Consolo et at. , 1987) and decreases the
output of striatal ACh measured by microdialysis in vivo
(Consolo et at. , 1987; Bertorelli and Consolo, 1990; Damsma
et at. , 1991; Imperato et at. , 1993). Dual dopaminergic mech-
anisms for the modulation of striatal ACh output, consisting
of D2-mediated inhibition as well as D1-mediated excitation,
can thus be demonstrated when receptor-subtype selective
DA compounds are systemically administered to intact am-
mals, regardless of whether tissue ACh content or extracel-
lular ACh level is the dependent variable.
Regarding the regulation of striatal ACh output by DA
receptor subtypes by endogenous DA, it is difficult to recon-
cile results from studies using tissue vs. microdialysis ap-
proaches to examine the effects of systemic administration of
indirect DA agonists. Increasing endogenous DA release by
administration of the indirect DA agonist AMPH inhibits
striatal ACh utilization based on tissue ACh measurements
(Sethy and Van Woert, 1974; Ladinsky et at. , 1975). However,
this latter effect is of a lesser magnitude than that seen with
direct D2-selective agomsts (Consolo et at. , 1987). When stri-
atal ACh output is measured with in vivo microdialysis,
administration of a variety of indirect DA agonists including
AMPH (Damsma et at. , 1991; Consolo et at. , 1992; Florin et
at. , 1992; Guix et at. , 1992), cocaine (Consolo et at. , 1992),
nomifensine (Damsma et at. , 1991), pargyline (DiChiara et
at. , 1993), and L-DOPA (DeBoer et at. , 1993), consistently
stimulates the output of striatal ACh. The increase in ACh
output produced by AMPH in vivo is reversed to an inhibition
by pretreatment with the Di-selective antagonist
SCH-23390 (Damsma et at. , 1991). Thus, although data from
both approaches indicate the existence of opposing dopamin-
ergic influences upon striatal ACh when endogenous DA is
increased, the studies using tissue measures of striatal ACh
content suggest a predominant D2-mediated inhibition
whereas in vivo microdialysis determinations demonstrate a
prevalence of D1-mediated excitation under similar condi-
tions.
A potentially important difference in the tissue content vs.
the in vivo microdialysis paradigms is the use of AChE in-
hibitors in the microdialysis perfusion fluid to increase the
yield of ACh from striatum. Local inhibition of AChE is
well-known to result in significant increases in basal levels of
ACh detected in extracellular fluid using in vivo microdialy-
sis (Damsma et at. , 1988; DeBoer et at. , 1990a; Cuadra et at.,
1994) and there is evidence indicating that pharmacological
responsivity of striatal cholinergic neurons may be altered
under these conditions. Early on, the inability of dopaminer-
gic stimulation to alter spontaneous striatal ACh effiux in
vivo (Jones et at. , 1973) was tentatively ascribed to the nec-
essary presence of the AChE inhibitor physostigmine in the
perfusion solution (Guyenet et at. , 1975). Furthermore, re-
cent studies directly demonstrate that increased cholinergic
tone secondary to AChE inhibition can alter the regulation of
striatal ACh output by muscarinic autoreceptors in vivo
(Damsma et at., 1988; DeBoer et at., 1990a) and can impair
D2-mediated inhibition of striatal ACh output in vitro
(Drukarch et at. , 1990).
The goal of our studies was to demonstrate the relative
contribution of DA receptor subtypes to the modulation of
striatal ACh release using in vivo microdialysis under phys-
iological conditions, i.e. , without the addition ofAChE inhib-
itor to the perfusate solution. To more systematically exam-
me the possibility that dopaminergic modulation of striatal
ACh output in vivo might vary as a function of local extra-
cellular ACh level, we also have carried out a comparison of
the responsivity of the ACh system to administration of do-
paminergic compounds in the presence of varying concentra-
tions of the AChE inhibitor NEO in the microdialysis perfus-
ate.
Methods
Animals. Adult male Sprague-Dawley rats (Zivic-Miller Labora-
tories, Pittsburgh, PA) weighing 350 to 550 g were used. The animals
were housed individually in plastic shoebox cages under conditions of
constant temperature (21#{176}C)and humidity (40%) on a 12:12 light:
dark cycle (07:00 on and 19:00 ofT). Food and water were available ad
libitum. During microdialysis experiments, the animals were kept in
Plexiglas cylinder cages. Animal procedures were conducted in ac-
cordance with guidelines published in the NIH Guide for the Care
and Use ofLaboratory Animals and all protocols were approved by
the Rutgers University Institutional Animal Care and Use Commit-
tee.
Drug treatments. Dopaminergic agonists and antagonists were
administered i.p. in a volume of 1 ml salinelkg(0.9% NaCl in distilled
water) except for haloperidol, which first was dissolved in a drop of
glacial acetic acid and then diluted to the desired concentration. In
studies examining the effect of AChE inhibition on the pharmaco-
logical responsivity of striatal ACh output, the AChE inhibitor NEO
was locally applied into striatum via the microdialysis probe. For
these studies, the NEO was dissolved in the microdialysis perfusate
immediately before the start ofthe experiment. Before initiating any
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pharmacological manipulation, base-line samples were collected and
analyzed until less than 30% sample-to-sample variation in ACh
level was obtained.
Microdialysis probe construction. The microdialysis probes
used in the present investigation were of the vertical, concentric
type. Two versions of this basic probe design were used, however,
depending on whether experiments were performed in the absence or
presence of NEO in the microdialysis perfusion fluid.
For the experiments conducted without AChE inhibition, microdi-
alysis probes with a relatively smaller diameter (O.D. 160 p.m) were
constructed in an attempt to minimize tissue damage during the
probe implantation. During pilot phases ofthis study it was observed
that minimization of tissue damage during implantation of the mi-
crodialysis probe was correlated with better chromatographic results
regarding separation ofACh from the solvent front. For these small-
diameter microdialysis probes, a piece of fused silica capillary
(Polymicro Technologies, Phoenix, AZ) with I.D. 50 .tm and O.D. 115
.tm was threaded into a piece of PE-lO tubing (Clay Adams, Parsip-
pany, NJ) through a small opening approximately 5 mm from the
end. The silica was positioned to extend past the end of the PE-lO
tubing. The exposed silica then was covered by an 8 mm length of
dialysis membrane hollow fiber (Spectra/Por, Spectrum, Houston,
TX) with an I.D. of 150 tm and an O.D. of 160 pm. The dialysis fiber
was glued into place within the lumen of the PE-lO tubing and the
tip was sealed with epoxy (Devcon, Danvers, MA). The fused silica
then was brought into close apposition to the closed end of the
dialysis membrane and epoxied into position at the junction of the
silica and PE-lO tubing. The portion ofthe dialysis membrane above
the desired active area (3 mm) was coated with a thin layer of epoxy.
Approximately 5 mm above the junction of the silica and PE-lO
tubing, an inletline (PE-lO, 40 cm) was epoxied over the silica and an
outlet line (fused silica, I.D. 75 .tm and O.D. 150 .tm) was epoxied
into the PE-lO tubing. Although these smaller diameter probes were
used successfully on a regular basis for measurements ofACh under
0 NEO conditions, these probes were in general more problematic
being prone to high back-pressures and leakage over time. In most
cases, therefore, the flow rate used with this probe design was 1.0
.tl/min (n = 15) however, in some instances (n = 5), a rate of 1.5
tl/min was used. The basal amount of ACh obtained in 20-pi dialy-
sate samples did not differ significantly between these two rates of
flow [t(18) = 1.87, P = .078].
Experiments carried out in the presence of an AChE-inhibitor in
the perfusion fluid were performed using microdialysis probes of
O.D. 250 pm and having an active length of 2 mm (Abercrombie and
Finlay, 1991). A piece ofPE-20 tubing(Clay Adams, Parsippany, NJ)
served as the inlet line ofthese probes, whereas a piece offused silica
capillary (I.D. 75 tm and 0.D. 150 tim) served as the outlet. Thus,
the direction of flow through the large-diameter probe was reversed
compared to the small-diameter probe design described above. The
standard rate of flow used with these probes was 1.5 .tl/min.
Over the course of our investigation, it was empirically deter-
mined that microdialysis probes of either diameter could be used to
sample ACh from striatal extracellular fluid, independent of whether
NEO was present in the perfusate. Careful surgical procedure,
rather than microdialysis probe diameter, therefore appeared to be
the critical factor for success with this approach (see below).
Microdialysis probe implantation. The dialysis probe was per-
fused continuously with aCSF (NaC1 147 mM, KC1 2.5 mM, CaCl2 1.3
mM, and MgCl2 0.9 mM, pH = 7.4) by means of a microliter syringe
pump (Harvard Apparatus Inc., South Natick, MA). The microdialy-
sis probes were implanted into striatum under chloral hydrate an-
esthesia (400 mg/kg i.p.) at the following coordinates: AP + 1.0 mm,
ML +2.5 mm relative to bregma and -6.0 mm below dura (Paxinos
and Watson, 1986). Extreme care was exercised to ensure that no
blood was present in the vicinity ofthe probe site. Entry ofthe probe
into the brain was monitored under a surgical microscope to be
certain that no tissue deflection occurred during this event. The
probe was lowered through the brain tissue using a microdrive
(Narishige, Japan) or an electrode carrier (no. 1760, David Kopf,
Tujunga, CA) at a speed of approximately 400 m/min and was
secured to the skull with three set-screws and fast-curing dental
cement. The inlet and outlet lines of the microdialysis probe were
guided along a metal tether that was secured to the skull with
fast-curing dental cement at one end and connected to a single-
channel fluid swivel (Instech Laboratories, Plymouth Meeting, PA)
at the other. Microdialysis experiments were conducted 16 to 20 hr
after probe implantation, at which time animals displayed normal
diurnal patterns of activity and normal levels of food and water
intake.
Analysis of dialysate. Dialysate was collected off-line at 15- or
20-mm intervals and 20-tl were analyzed for ACh by high perfor-
mance liquid chromatography. ACh was separated on a cation-ex-
change column prepared by loading a reverse-phase column ( 100 x
2.0 mm), filled with Chromspher 5C18 packing material
(Chrompack, Middelburg, The Netherlands), with a sodium lauryl
sulfate ion-pairing solution (Damsma and Westerink, 1991). An en-
zymatic postcolumn reactor was used for the generation of hydrogen
peroxide from catabolized ACh and was prepared by loading a guard
column (10 x 1.0 mm or 10 x 2.0 mm) with Lichrosorb-NH2 (Merck,
Darmstadt, F.R.G.). After loading, 1 ml of 25% glutaraldehyde solu-
tion was pumped through the guard column at a flow rate of 100
L1/min in order to activate the Lichrosorb-NH2. Immediately after
activation, enzymes were covalently immobilized on the activated
matrix by passing 500 tl of a solution containing 40 U choline
oxidase and 80 U AChE in 0.1 M potassium phosphate buffer (pH =
8.0) through the guard column at a flow rate of 50 .tIJmin. The
enzyme reactor thus prepared was rinsed with buffer for an addi-
tional 30 mm at a flow rate of 400 tl/min before use. The hydrogen
peroxide generated by the enzyme reactor was quantified using a
platinum wall-jet electrode (ANTEC, Leiden, The Netherlands) set
at +550 mV us. Ag/AgC1. The mobile phase was a 0.1 M potassium
phosphate buffer (pH = 8.0) containing 1.5 mM tetramethylammo-
nium chloride, 1.5 mM sodium octyl sulfate and 0.1 mM disodium
ethylenediamine tetraacetate and was delivered at a flow rate of 350
to 450 .tl/min by either a Waters model 510 HPLC pump (Waters
Chromatography Division, Milford, MA) or an ESA model 580 HPLC
pump (ESA, Bedford, MA).
The detection limit of the present assay was -5 to 10 fmol ACh.
This sensitivity exceeds to 10 to 50 fmol detection limit of previously
described methods for measurement of very low quantities of ACh
(Damsma et al., 1988; DeBoeret al., 1990b). A combination of regular
replacement of the analytical column and enzyme reactor, as well as
cleaning of the working electrode (weekly or biweekly) resulted in
consistently high sensitivities for ACh. Figure 1 shows example
chromatograms representing the output of striatal ACh in the ab-
sence ofNEO, in the presence of 10 aM NEO and as decreased by the
D2-selective agonist quinpirole (3 mg/kg i.p.) in the presence of 10
nM NEO.
Data analysis. The amount of ACh obtained in the dialysate
fractions was calculated as fmolJ2O-pi sample. These values were not
corrected for the in vitro recovery of the dialysis probes because
defective probes were excluded from use and the variability in this
measure among probes was therefore negligible (<2%). Group values
are mean ± S.E.M. For the analysis ofwithin-group drug effects, the
fmol ACh value for the final base-line sample and values for six
samples collected immediately after drug administration were com-
pared using one-way ANOVA with repeated measures over time (P 
.05) followed by Dunn’s post hoc test. Unless otherwise stated, sig-
nificant drug effects lasted for the entire duration ofthe experiment.
For clarity of presentation, therefore, the base-line value and the
peak significant effect value (derived from the post hoc analysis) are
provided for each condition. For those treatment groups in which
statistical analysis did not result in an overall significant F ratio, the
ACh value corresponding to the fourth sample after drug adminis-
tration arbitrarily was chosen for presentation. The relation between
the absolute change in ACh output produced by administration of the
C. NEO=1O nM D. QUINPIROLE
(41 fmol) (nd.)
A. Standard B. Basai
(200 fmol) (23 hno
4
8 Mln
778 DeBoer and Abercrombie Vol. 277
___ 4 4
Fig. 1. Chromatograms obtained sequentially during the course of a
single microdialysis experiment. The ACh peaks are indicated by ar-
rows. All samples were 20 .tl in volume. A, Chromatograph response to
injection of standard solution containing 200 fmol ACh. The negative
deflection prior to the ACh peak represents a manual adjustment of the
strip chart recorder pen. B, ACh obtained in stnatal dialysate under 0
NEO conditions. C, Increase in stnatal ACh output induced by the
presence of 10 nM NEO in the aCSF. D, Effect of quinpirole (3 mg/kg
i.p.) on stnatal ACh output in the presence of 10 nM NEO in the aCSF.
direct DA agonists quinpirole and SKF-38393 and basal ACh level
under conditions of varying NEO concentration was evaluated ac-
cording to a simple linear regression model. The fit ofthe model thus
obtained was assessed by one-way ANOVA (P  .05). The effect of
AMPH and AMPH + SCH-23390 on the time-course of quinpirole-
induced decreases in striatal ACh output was compared to the effect
of quinpirole alone using two-way ANOVA with repeated measures
over time (P  .05) followed by Dunnett’s post hoc test. The level of
significance of all post hoc analyses was P  .01.
Materials. Acetylcholinesterase type VI-S, d-asnphetamine sul-
fate, choline oxidase, haloperidol and neostigmine bromide were
purchased from Sigma Chemical Co. (St. Louis, MO). Quinpirole
hydrochloride (LY171555) was obtained from Eli Lilly & Co. (India-
napolis, IN). R(+)-SKF-38393 HCI and R(+)-SCH-23390 HCI were
purchased from Research Biochemicals Inc. (Natick, MA). All other
reagents and chemicals were of analytical grade and were obtained
from Fisher Scientific (Springfield, NJ).
TABLE 1
Results
Effect of aCSF NEO concentration on striatal ACh
output. Without addition of the AChE inhibitor NEO to the
aCSF, technical difficulties were such that detectable ACh
levels were obtained in striatal dialysates from approxi-
mately 50% of animals attempted. In these cases, the output
of striatal ACh was 25.1 ± 2.2 fmol/20-pi sample (n = 20).
The basal level ofACh in striatal dialysates was 67.9 ± 3.5 (n
= 35) and 527.7 ± 56.1 (n = 13) fmol/20-pi sample in the
presence of 10 and 100 nM NEO, respectively.
Effect of DA agonists on striatal ACh output in the
absence of AChE inhibition. The data concerning the ef-
fect of DA agonists on striatal ACh output in the absence of
AChE inhibition are summarized in table 1. The indirect DA
agonist AMPH, administered at a dose of 2 mg/kg, did not
alter the extracellular level ofACh in striatum in the absence
ofNEO in the aCSF (from 31.3 ± 5.1 to 30.4 ± 6.5 fmol/20 p1)
A [F(6,30) = 0.84, P = .55; n = 6]. Under these conditions, a 10
T mg/kg dose of AMPH significantly decreased striatal ACh
output from 29.6 ± 2.5 to 19.3 ± 1.6 fmol/20 p1 [F(6,24) =
4.66, P = .003; n = 5]. AMPH administration triggered an
increase in locomotor activity that was preceded, at the
higher dose of the drug, by an initial phase of focussed ate-
reotypy.
The D2-selective agonist quinpirole (3 mg/kg) significantly
decreased striatal ACh output from 21.1 ± 4.2 fmol/20 p1 to
levels at or below the detection limit of the assay (5 to 10
fmol) in the absence of NEO in the aCSF [F(6,18) = 13.90, P
< .001; n = 4]. Quinpirole caused an initial burst of locomotor
activity that was followed by focussed stereotypy and periods
of immobility.
Administration of the D1-selective agonist SKF-38393 (10
mg/kg) elicited a significant increase in the output of striatal
ACh, from 18.3 ± 1.8 to 25.1 ± 1.5 fmolJ2O p1, without NEO
in the aCSF [F(6,24) = 5.12, P = .002; n = 5]. This increase
in extracellular ACh was transient, occurring only in the
sample corresponding to 15 to 30 mm after drug injection
(data not shown). The injection of SKF-38393 was accompa-
nied by an increase in locomotor activity of approximately
30-mm duration.
Effect of AChE inhibition on striatal ACh output in
response to DA agonists. The data concerning the effect of
DA agonists on striatal ACh output in the presence of AChE
inhibition are summarized in table 1. Similar to the 0 NEO
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condition, the indirect DA agonist AMPH at the 2 mg/kg dose
did not affect striatal ACh output when 10 nM NEO was
perfused in the aCSF (from 62.0 ± 6.5 to 63.7 ± 9. 1 fmol/20
p1) [F(6,24) = 0.59, P = .73; n = 5]. However, this dose of
AMPH produced a significant increase in the output of stri-
atal ACh, from 580.4 ± 104.2 to 969.6 ± 146.1 fmol/20 p1,
when 100 nM NEO was present [F(6,24) = 8.30, P < .001; n
= 5]. In the presence of 10 nM NEO, administration of 10
mg/kg AMPH produced a nonsignificant decrease in striatal
ACh efflux (from 62.5 ± 8.7 to 54.1 ± 9.2 fmol/20 p1) [F(6,24)
= 1.41, P = .25; n = 5].
In the presence of 10 nM NEO the D2-selective agonist
quinpirole (3 mg/kg) continued to elicit a significant de-
crease in extracellular ACh in striatum, from 72.8 ± 14.3
to 10.8 ± 2.0 fmol/20 p1 [F(6,24) = 14.7, P < .001; n = 5].
In the 100 nM NEO condition, quinpirole administration
was associated with a decrease in extracellular ACh that
was nonsignificant (from 604.2 ± 78.2 to 538.8 ± 83.2
fmolJ2O p1 [F(6,18) = 2.4, P = .07; n = 4]. The amplitude of
the inhibitory response to the D2 receptor agonist was
proportional to basal ACh level when the NEO concentra-
tion was 0 or 10 nM [r2 = 0.99; F(1,7) = 604.2, P < .00 1]
(fig. 2). The absolute changes in ACh output for these
groups were 11 fmol (based on a 10 fmol detection limit of
the assay) and 62.0 ± 13.2 fmol, respectively, as shown in
table 1. The amplitude of this response did not increase
further in the presence of 100 nM NEO ( = 65.4 ± 8.4
fmol; table 1) such that the relation between the quinpi-
role-induced inhibition of striatal ACh output and basal
ACh level across all NEO conditions was nonlinear [r2 =
0.17, F(1,11) = 2.31, P = .16] (fig. 2).
The D1-selective agonist SKF-38393 (10 mg/kg) continued
to produce significant increases in striatal ACh output in the
presence of 10 or 100 nM NEO in the aCSF. In the 10 nM
NEO condition, extracellular ACh was increased from 70.2 ±
8.7 to 94.3 ± 11.3 fmol/20 p1 by SKF-38393 [F(6,24) = 8.05,
P = .001; n = 5]. Striatal ACh efflux increased from 385.3 ±
83.1 to 516.2 ± 116.5 fmolJ2O p1 in response to SKF-38393 in
the 100 M NEO condition [F(6,18) = 5.57, P = .002; n = 4].













by SKF-38393 increased linearly as a function of basal ACh
level across all NEO conditions Er2 = 0.89; F(1,12) = 97.89, P
< 0.001] (fig. 2). The absolute change in ACh output pro-
duced by SKF-38393 was 6.8 ± 1.6 fmol in the absence of
NEO, 24. 1 ± 6.2 fmol in the 10 nM NEO condition, and 130.9
± 37.8 fmol in the 100 nM NEO condition (table 1). The
duration of the increase in striatal ACh output produced by
SKF-38393 progressively lengthened as the applied NEO
concentration was increased (data not shown). The presence
of NEO in the aCSF did not detectably alter the behavioral
response to any of the drugs administered.
Role of DA receptor subtypes in the regulation of
striatal ACh output by indirect DA agonist. The contri-
butions of D2 and Dl receptors to the effects of systemic
AMPH on striatal ACh efflux were examined in the presence
of 10 nM NEO in the aCSF (fig. 3). The D2-selective agonist
quinpirole (3 mg/kg) was administered, causing an 85% de-
crease in striatal ACh output (n = 5). A subsequent injection
of AMPH (5 mg/kg) elicited a significant increase in the
output of striatal ACh relative to the effect of quinpirole
alone [F(12,96) = 4.3, P < .001; n = 5]. The latter AMPH-
induced increase in ACh then could be reversed to levels no
longer significantly different from quinpirole alone by admin-
istration of the Dl antagonist SCH-23390 (0.5 mg/kg). ACh
output remained significantly elevated relative to the effect
of quinpirole alone for the duration of the experiment if
SCH-23390 was not administered [F(12,84) = 7.98, P < .001;
n = 4].
Effect of DA antagonists on striatal ACh output.
The effects of the D2 receptor antagonist haloperidol (1
mgfkg) and of the Dl receptor antagonist SCH-23390 (0.5
mgfkg) on striatal ACh output were assessed in the pres-
ence of 10 nM NEO in the aCSF (fig. 4). Haloperidol
significantly increased the output of striatal ACh from
57.9 ± 5.6 to 86.8 ± 10.0 fmol/20 p.l [F(6,24) = 2.59, P =
.04; n = 5]. In contrast, SCH-23390 significantly decreased
extracellular ACh from 80.7 ± 7.2 to 48.0 ± 5.6 fmol/20 p1
{F(6,24) = 7.23, P = .002; n = 5]. Both drugs produced
immobility in the experimental animals.
Basal ACh (tmol)
Fig. 2. Relation between the absolute change in ACh output produced by administration of the D2-selective agonist quinpirole (3 mg/kg i.p.) or
the Dl -selective agonist SKF-38393 (1 0 mg/kg i.p.) and basal ACh level under conditions of varying NEO concentration. The absolute ACh
response to drug treatment and the basal ACh level for each animal were obtained based on the baseline and peak effect values used to calculate
the group means presented in table 1 . The solid line indicates the relation between the two variables derived from a simple linear regression model.
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Fig. 3. Role of DA receptor subtypes in the regulation
of striatal ACh output by indirect DA agonist. Experi-
ments were conducted in the presence of 10 nM NEO
in the aCSF. The direct D2 agonist quinpirole (3 mg/kg
p.) was administered at the first arrow. The time
course data for quinpirole-induced decreases in stria-
tal ACh output (solid bars) are from the group repre-
sented in table 1 . In a separate group (lightly hatched
bars), the quinpirole-induced decrease in striatal ACh
output was significantly reversed by the indirect DA
agonist AMPH (5 mg/kg i.p., second arrow). In another
group (darkly hatched bars), this latter effect subse-
quently was blocked by the Dl antagonist SCH-23390
(0.5 mg/kg p., third arrow). Data are fmol ACh/20 .tl
(mean ± S.E.M.).    .01 vs. quinpirole alone.
BL PEAK BL PEAK
HAL SCH
Fig. 4. Effect of the D2 antagonist haloperidol (1 mg/kg p.) or the Dl
antagonist SCH-23390 (0.5 mg/kg p.) on striatal ACh output. Experi-
ments were conducted in the presence of 10 nM NEO in the aCSF. The
predrug base-line (BL) value and peak drug effect are given as fmol
ACh/20 M1 (mean  S.E.M.).   < .01 vs. BL.
Discussion
The effect of systemic administration of various dopamin-
ergic agonists upon the output of striatal ACh was deter-
mined using in vivo microdialysis under physiological condi-
tions, i.e. , no AChE inhibitor was added to the microdialysis
perfusate in these experiments. To increase the yield of ACh
from the extracellular space, the addition of such compounds
to the perfusate at concentrations ranging from 100 nM to 10
MM is typical procedure for in vivo microdialysis studies.
Under physiological conditions, increasing endogenous DA
release by administration of the indirect DA agonist AMPH
produced either no change (2 mg/kg) or a decrease (10 mg/kg)
in striatal ACh output. These findings differ from the results
of recent in vivo microdialysis studies, conducted in the pres-
ence of AChE inhibition, in which similar doses of AMPH
elicit a stimulation of striatal ACh efflux (Damsma et al.,
1991; Consolo et al., 1992; Florin et al., 1992; Guix et al.,
1992). However, our results are entirely consistent with pre-
vious studies of the effect of systemically administered mdi-
rect DA agonists on striatal tissue ACh levels in which either
no change or a decrease in ACh utilization is observed and
signs of increased ACh activity never are found (Sethy and
Van Woert, 1974; Ladinsky et al., 1975; McGeer et al., 1975;
Consolo et at., 1987).
In the absence of AChE inhibition, systemic administra-
tion of the D2-selective agonist quinpirole decreased extra-
cellular ACh in striatum to nondetectable levels whereas the
Di-selective agonist SKF-38393 significantly increased this
measure. The data obtained with the direct agonists gener-
ally corroborate previous results obtained both in vivo (Ber-
torelli and Consolo, 1990; Damsma et al. , 1990a, 1990b, 1991)
and from tissue determinations (Scatton, 1982a, 1982b; Con-
solo et al. , 1987) although the relative magnitude of the
D2-mediated decrease in ACh efflux was greater under the
physiological conditions of our study than has been reported
in previous in vivo studies utilizing AChE inhibitors (Ber-
torelli and Consolo, 1990; Damsma et al. , 1990a; Imperato et
at. , 1994). Both the present data as well as other in vivo
microdialysis studies consistently demonstrate increases in
striatal ACh output in response to the Dl agonist SK.F-38393
whereas tissue determinations of striatal ACh utilization
have failed to detect this stimulatory action of the drug
(Scatton, 1982a; Consolo et at., 1987). Because we observed
that the increase in striatal ACh output produced by sys-
temic SKF-38393 in vivo was quite transient in the absence
of NEO, it is likely that such an effect could be missed in
studies using tissue ACh measures depending on the time
after drug administration that the tissue was obtained.
The degree to which the dopaminergic modulation of stri-
atal cholinergic neurons might vary as a function of local
extracellular ACh level also was directly examined in our
studies. The AChE inhibitor NEO was applied via the micro-
dialysis perfusate at a concentration of either 10 or 100 nM
and the effect of systemic administration of the DA agonists
on striatal ACh output under these conditions was deter-
mined. The addition of NEO to the aCSF caused a dose-
related increase in the basal extracellular concentration of
striatal ACh. The effects ofAMPH administration on striatal
ACh efflux were not qualitatively altered by the presence of
10 nM NEO. At this NEO concentration, 2 mg/kg AMPH
continued to be without effect on ACh output and 10 mg/kg
AMPH continued to produce a decrease although this effect
was no longer statistically significant. In contrast, when the
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crease in ACh output occurred in response to administration
of the 2 mg/kg dose ofAMPH (table 1). This profile of cholin-
ergic responsiveness to systemic AMPH in the presence of 10
and 100 nM NEO recently has been independently replicated
(Acquas and Fibiger, 1995). It would thus appear that do-
paminergic regulation of striatal ACh output is altered in a
way dependent on the degree of AChE inhibition that exists
when microdialysis measurements are conducted.
Examination of the effects of direct DA agonists on ACh
output in the presence of 10 and 100 aM NEO provided a
basis for better understanding the AMPH-induced increase
in ACh efflux that was uniquely observed in the presence of
100 nM NEO. The effect of the D2 agonist quinpirole was to
inhibit ACh output in all the NEO conditions but the de-
crease observed in the 100 nM condition was not statistically
significant. When the Dl agonist SKF-38393 was adminis-
tered, striatal ACh output was significantly increased in all
NEO conditions (table 1). Whereas the amplitude of D2-
mediated ACh inhibition increased in proportion to basal
ACh level in the presence of 0 and 10 nM NEO but did not
increase further at 100 nM NEO, the amplitude of the Dl-
mediated excitation continued to grow in linear relation to
basal ACh level across all NEO concentrations examined (fig.
2). A model based on these differing response patterns for
D2-mediated inhibition vs. D1-mediated excitation of striatal
ACh in the presence of varying concentrations of NEO is
depicted in figure 5. This model is proposed as a basis to help
explain the effects of the indirect DA agonist AMPH on
striate.! ACh output under conditions of varying AChE inhi-
bition. The action ofAMPH can be no net change or a D2-like
decrease in the output of striatal ACh when no AChE inhib-
itor is used or when AChE inhibitor is present in low concen-
tration (our study). In contrast, AMPH may elicit a Di-like
stimulation ofstriatal ACh output when higher levels of ACh
inhibitor are present (Damsma et at. , 1991; Consolo et at.,
1992; Florin et at. , 1992; Guix et at. , 1992). Thus, the conclu-
sion derived in previous microdialysis studies that systemic
AMPH preferentially stimulates the output ofACh from stri-
atum via an action at Dl receptors appears applicable only to
this latter situation. In agreement with previous studies of
Basal ACh
Fig. 5. A model for the effects of indirect agonists such as AMPH on the
output of stnatal ACh under varying conditions of AChE inhibition. The
model is based on the results obtained in our studies for ACh re-
sponses to systemic administration of selective 02 and Dl agonists
(fig. 2). As basal ACh level increases with increasing AChE inhibition,
differential response amplitude profiles for D2-mediated suppression
vs. Dl -mediated excitation of stnatal ACh output are obtained. The
model predicts that the ACh response to administration of an indirect
DA agonist will be predominantly D2-like when basal ACh level is
relatively low and predominantly Dl -like when basal ACh level is suffi-
ciently elevated.
tissue ACh utilization, our measurements indicate that in-
hibitory D2 receptor regulation of striatal ACh output equals
or exceeds the opposing excitatory Dl influence when endog-
enous DA is increased by AMPH under physiological condi-
tions. Furthermore, it is probable that this model extends to
indirect DA agonists other than AMPH because we observed
a similar effect of NEO concentration on the response of
striatal ACh to L-DOPA (DeBoer et at. , 1993; Wachtel and
Abercrombie, 1993).
To test more directly the hypothesis that the effects of
systemic AMPH on striatal ACh output can be understood in
terms of DA acting on both D2 and Dl receptors, we exam-
med whether AMPH administration could elicit a reversal of
the D2-mediated inhibition of striatal ACh output produced
by quinpirole. In the presence of 10 nM NEO, quinpirole
decreased striatal ACh efflux by 85% and we observed a
significant increase in ACh output on subsequent adminis-
tration of AMPH relative to the level of ACh output mea-
sured after quinpirole alone (fig. 3). This excitatory action of
AMPH was abolished by administration ofthe Dl antagonist
SCH-23390, indicating that it was Dl mediated. These re-
suits as well as the results of others (Damsma et at. , 1991;
Consolo et at. , 1992), provide evidence that the action of
AMPH on striatal ACh efflux in vivo can be understood by
assuming that this drug concurrently acts at inhibitory D2
and stimulatory Dl receptors. Moreover, it appears that both
of these opposing dopaminergic influences also are involved
in the tonic regulation of striatal ACh output in the non-drug
state. We observed, in the presence of 10 nM NEO, that
systemic administration of the D2-selective antagonist halo-
peridol increased ACh efflux whereas the Di-selective antag-
onist SCH-23390 decreased this measure (fig. 4). The mag-
nitude of these antagonist effects was comparable to values
previously reported in the literature (Bertorelli and Consolo,
1990; Damsma et at. , 1990a, 1991; Imperato et at. , 1993).
In our studies, we observed a shift to a relative predomi-
nance ofDl-mediated excitation ofACh output in the 100 nM
NEO condition. This phenomenon appeared to be due to a
ceiling effect governing the amplitude of D2-mediated inhi-
bition of ACh output and is presumed to occur secondary to
the large elevation in basal extracellular ACh level produced
by the presence of a high concentration of AChE inhibitor
(fig. 5). The underlying mechanisms that are the basis for
this effect are unknown but the following possibilities are
suggested by available data. 1) Previously, it has been shown
that infusion of AChE inhibitor attenuates the ability of
muscarinic autoreceptor agonists to inhibit striatal ACh out-
put and increases the effectiveness of muscarinic antagonists
in increasing this measure (Damsma et at. , 1988; DeBoer et
at. , 1990a). These data indicate that AChE inhibition in-
creases the occupation of muscarinic autoreceptors by endog-
enous ACh. In vitro, Drukarch et at. (1990) showed that
increases in muscarinic autoreceptor stimulation attenuated
the responsiveness of striatal ACh to D2 stimulation and it
was hypothesized that muscarinic autoreceptors and D2 re-
ceptors on striatal cholinergic interneurons share a common
transduction mechanism. Such a mechanism may involve
regulation of a single population of K channels. 2) Cholin-
ergic interneurons have reciprocal connections with the me-
dium spiny output neurons ofthe striatum that use GABA as
their primary transmitter (Phelps et at. , 1985; Bolam et at.,
1986; Izzo and Bolam, 1988; Martone et at., 1992). ACh has
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been shown to increase the release of GABA through both
muscariic and nicotiic mechanisms (Van der Heyden et at.,
1980; Girault et at. , 1986). Changes in the cholinergic mod-
ulation of cellular interactions within the striatal cell mosaic
induced by high extracellular levels of ACh could, in turn,
alter the pharmacological responsiveness of cholinergic neu-
rons to D2 stimulation.
In summary, we observed that the release of striatal ACh
is influenced by both an inhibitory D2 mechanism as well as
by an excitatory Dl mechanism. Both mechanisms are oper-
ative in the tonic regulation of striatal ACh output and in
determining the ACh response to systemic administration of
the indirect DA agonist AMPH. Under physiological condi-
tions, D2-mediated inhibition of striatal ACh output equals
or exceeds D1-mediated excitation. The predominant dopam-
inergic influence on ACh output shifts in favor of Dl-medi-
ated excitation when extracellular ACh levels are increased
by local application of AChE inhibitor in high concentration.
Previous microdialysis studies assessing the role of DA re-
ceptor subtypes in the regulation of striatal ACh output have
been conducted in the presence of high concentrations of
AChE inhibitors. As a result, these studies tend to underes-
timate the magnitude of D2-mediated inhibition of striatal
ACh and are inherently biased toward detection of Di-medi-
ated excitatory effects in response to systemic administration
of indirect DA agonists such as AMPH.
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